XNAS · Healthcare · Medical Devices
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-06 | Q1 2026 | 1.18 | 1.42 | +20.34% | $761.7M | ✅ Beat | +4.81% | -1.61% | — |
| 2026-02-18 | Q4 2025 | 1.47 | 1.55 | +5.44% | $783.8M | ✅ Beat | +0.82% | -3.86% | -12.00% |
| 2025-11-06 |
| Q3 2025 |
| 1.14 |
| 1.24 |
| +8.77% |
| $706.3M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-07 | Q2 2025 | 0.93 | 1.17 | +25.81% | $649.1M | ✅ Beat | +4.58% | +4.03% | +14.79% |
| 2025-02-20 | Q4 2024 | 1.02 | 1.15 | +12.75% | $597.5M | ✅ Beat | -1.90% | -7.35% | -4.94% |
| 2024-11-07 | Q3 2024 | 0.76 | 0.90 | +18.42% | $543.9M | ✅ Beat | +9.40% | +6.60% | +8.22% |
| 2024-02-22 | Q4 2023 | 0.66 | 1.40 | +112.12% | $509.8M | ✅ Beat | — | — | — |
| 2023-11-02 | Q3 2023 | 0.40 | 0.71 | +77.50% | $432.7M | ✅ Beat | +15.76% | +8.86% | +38.13% |
Showing last 8 quarters.